Previous 10 | Next 10 |
home / stock / kykof / kykof news
2023-09-24 23:33:31 ET Summary Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been poor, but the partnership with Amgen provides rea...
2023-08-04 13:20:08 ET Kyowa Kirin press release ( OTCPK:KYKOF ): H1 GAAP EPS of ¥40.27 Revenue of ¥199.2B, vs. ¥185.3B last year. For further details see: Kyowa Kirin reports H1 results
2023-05-10 19:02:06 ET Kyowa Kirin press release ( OTCPK:KYKOF ): Q1 GAAP EPS of ¥23.74. Revenue of ¥93.54B (+6.6% Y/Y). For further details see: Kyowa Kirin GAAP EPS of ¥23.74, revenue of ¥93.54B
2023-04-25 04:31:23 ET Summary Kirin Holdings is executing positive price hikes, business portfolio management, and a greater commitment to raising profitability. Earnings visibility looks positive, with continued price increases in beverages, steady overseas expansion, and steady...
Kyowa Kirin Co., Ltd. press release ( OTCPK:KYKOF ): FY GAAP EPS of ¥99.66. Revenue of ¥398.37M (-99.9% Y/Y). For further details see: Kyowa Kirin Co., Ltd. GAAP EPS of ¥99.66, revenue of ¥398.37M
Kyowa Kirin Co., Ltd. press release ( OTCPK:KYKOF ): 9M GAAP EPS of ¥91.55. Revenue of ¥283.77B (+11.7% Y/Y). For further details see: Kyowa Kirin GAAP EPS of ¥91.55, revenue of ¥283.77B
The Seeking Alpha Quant system has its quirks, but it is a great tool to find great holdings. I typically dredge through the weeds to find unique situations that may be unloved by the quant system. However, here are five strong buys that I agree with right now. Optimizin...
Kirin announced a credible medium-term plan, highlighting opportunities for growth and improving profitability. There are limits to what Kirin can achieve in the face of current inflationary cost pressures, and the domestic price hike announcement highlights its significance. Cons...
Kyowa Kirin ( OTCPK:KYKOF ) expands the license agreement with Synaffix, by adding one new ADC to a total of three ADC programs. Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target. ...
The European Union drug regulator's human medicines committee has recommended extending the indication of Koywa Kirin's (OTCPK:KYKOF) Crysvita medicine, according to the highlights of their latest meeting. Crysvita is manufactured by the Japanese pharmaceutical company and distributed by U.S....
News, Short Squeeze, Breakout and More Instantly...
Kyowa Hakko Kogyo Company Name:
KYKOF Stock Symbol:
OTCMKTS Market:
TOKYO , Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto , "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patie...